Mustang Bio

Immunotherapies

MB-207 Clin1 XSCID; MB-106 Clin1 NHL, CLL; MB-102 Clin1/Clin2 BPDCN; MB-101 Clin1 glioblastoma; MB-108 Clin1 glioblastoma; undisclosed RD/Clin0 undisclosed

Mustang Bio is a clinical-stage biopharmaceutical company headquartered in Worcester, Massachusetts and founded in 2015. Their mission is to translate groundbreaking scientific discoveries in cell and gene therapy into potential cures for various diseases. Mustang Bio develops CAR T cell and lentiviral gene therapies to treat hematologic cancers like leukemia and lymphoma, solid tumors including glioblastoma, and X-linked severe combined immunodeficiency (X-SCID). Through partnerships with top medical institutions, Mustang Bio will be able to advance their development of CRISPR/Cas9 enhanced and classical CAR T therapies as well as lentiviral gene therapy.

Jobs: